H1 and H2 Blockade Around Mast-Cell Degranulation Risk

H1-receptor and H2-receptor blocking companion medicines is covered as protocol-linked supportive medicines; not direct antitumour treatment, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Protocol-linked supportive medicines; not direct antitumour treatment. Examples in the current Stelfonta label include diphenhydramine as an H1 blocker and famotidine as an H2 blocker; exact selection remains veterinary.

Examples in the current Stelfonta label include diphenhydramine as an H1 blocker and famotidine as an H2 blocker; exact selection remains veterinary.

H1 blockade reduces selected peripheral histamine effects, while H2 blockade reduces gastric acid secretion and other H2-mediated effects. These medicines do not prevent every mediator effect and do not kill the tumour.

The FDA Stelfonta label requires a corticosteroid plus H1 and H2 blockers to reduce severe systemic reactions from mast-cell degranulation. That label-specific requirement should not be converted into a universal at-home mast-cell protocol.

The FDA Stelfonta label requires a corticosteroid plus H1 and H2 blockers to reduce severe systemic reactions from mast-cell degranulation. That label-specific requirement should not be converted into a universal at-home mast-cell protocol.

Veterinarian-prescribed oral or injectable medicines linked to a defined mast-cell plan

The strongest boundary here is the current product label. Evidence and duration for other mast-cell tumours, surgery or spontaneous degranulation differ and require a veterinarian.

Sedation, excitation, anticholinergic effects, gastrointestinal change and drug-specific interactions can occur. Missing required companion medicines in the Stelfonta context has been associated with severe systemic reactions, including death.

The complete medication list matters, including sedatives, behavioural medicines, antiarrhythmics and other acid suppressants. H2 blockade in this context is not the same as routine long-term antacid use.

This is a companion-medication context page. Diphenhydramine and famotidine are not represented as FDA-approved antitumour drugs; use may be label-directed as a companion requirement or extra-label depending on the product and indication.

The cited Stelfonta requirement is the US label; verify regional product information elsewhere.

The treating clinic supplies the exact companion-medication plan and watches for vomiting, diarrhoea, swelling, hives, breathing change, hypotension, collapse and wound complications. Owners should not replace a missed prescribed medicine or alter the plan from this page.